BIONPHARMA
GenericsBIONPHARMA is a generic drug manufacturer focused on Neurology, Infectious Disease, Immunology.
BIONPHARMA's Key Drugs
BIONPHARMA's core commercial portfolio centers on DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, spanning Neurology and Infectious Disease — its most strategically important drugs approved in the last 15 years.
BIONPHARMA's Recent FDA Approvals
BIONPHARMA secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
BIONPHARMA's Therapeutic Areas
BIONPHARMA's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Infectious Disease, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
BIONPHARMA's Top Competitors
BIONPHARMA's closest competitors by therapeutic-area and drug-target overlap include GSK, Pfizer, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
BIONPHARMA Pipeline Snapshot
Active clinical trials for BIONPHARMA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (2)
Discontinued (2)
Company Info
- First Approval
- 1974-04-11
- Latest
- 2026-10-30
- Applications
- 82